Verastem, Inc. (VSTM) Discusses New Clinical Data for VS-7375 KRAS G12D Inhibitor in Pancreatic, Lung, and Colorectal Cancers Transcript

Verastem, Inc. (VSTM) presented new clinical data for VS-7375, a KRAS G12D inhibitor, showing promising results in pancreatic, lung, and colorectal cancers. The drug demonstrated significant anti-tumor activity and a manageable safety profile.